STUDresearch · Non-peptide

Rapamycin

Also known as

Sirolimus · Rapamune · Rapamune (brand) · Rapamune / sirolimus generics · AY-22989 (historical research designation) · mTOR inhibitor (class discussion) · Rapalog parent compound · Rapa (forum shorthand) · Sirolimus oral tablet / solution · Compounded rapamycin (clinic/telehealth form)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Lots of talk Systemic Oral Longevity & mTOR

Systemic — whole-body mTORC1 modulation via oral absorption; not a local/injury or peptide-style site-injection agent.

What people say Rapamycin is prescription sirolimus. Longevity forums discuss mTOR, mouse lifespan findings and hoped-for healthy aging. Human lifespan benefits are not established; it is a real immunosuppressant, not an ordinary supplement. Doses people talk about

Lower intermittent reports · off-label2–3 mg once weekly

Oral reports; formulation is not consistently specified in these logs. This is not a recommended starting point.

Frequently cited forum band · off-label5–7 mg once weekly

Oral commercial-tablet discussion; 6 mg is commonly repeated in the original notes.

Higher intermittent reports · off-label8–10 mg once weekly

Oral reports; product differences matter. These amounts are not a progression or assurance of tolerance.

Sirolimus is an immunosuppressant. Infection, wound-healing and interaction risks remain at intermittent amounts; compounded and commercial tablets can differ in exposure.

Half-life & effect duration

Half-life in the body: Rapamune · repeated-use label estimateAbout 62 hours — roughly 2.5 days
Felt duration people report: Some accountsSame-day energy or a few hours of tiredness
One combination accountA next-day effect lasting about a day
Other accountsNo noticeable effect or skin problems

Timing context & sources

How it may feel Some users describe more energy or better recovery; others feel nothing, or report fatigue, fog, GI trouble and mouth sores. A noticeable effect is not evidence of added lifespan.

Cycles people discuss The dominant longevity discussion is long-term intermittent use, often weekly. Four-to-eight-week breaks every few months also appear in clinic/forum lore; no superior on/off calendar is established. Timing A consistent weekday and food context are common habits; some users choose a rest day because of fatigue or training concerns. Grapefruit and interacting drugs change exposure, not just convenience. Stacks Metformin: Most-named dual stack — AMPK + mTOR nutrient-sensing; also discussed as metabolic offset for rapa-related glucose/TG drift. Doses are separate drugs (not a fixed ratio blend); common metformin talk is standard IR/XR clinical bands, not “X mg per mg rapa.” Watch for Infection risk: Real immunosuppressant class concern; intermittent low-dose does not erase it — pause talk on significant illness; rare serious infections still appear in case/trial commentary.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 62 hours—roughly two and a half days—in the Rapamune label's transplant data.

That is a blood-elimination estimate after repeated use, not the duration of mTOR effects or a validated weekly longevity schedule.

Stable renal-transplant patients are not healthy once-weekly users. Food, interactions, formulation and liver function can change exposure; mean 62 ±16 hours is not a personal countdown.

Rapamune: elimination and food effects (opens in a new tab)Section 12.3 Distribution and Excretion, multiple-dose stable renal-transplant half-life; Absorption, formulation-specific food effects.Not an mTOR-response duration or healthy-longevity outcome. Tablet/solution peak effects differ; compounded products are not covered by an assumed equivalence.

Felt duration people report

In one forum thread, reports range from same-day energy to tiredness for a few hours, a next-day effect lasting about a day, or no noticeable effect.

The next-day report included grapefruit and other supplements, so it cannot describe rapamycin alone. Other posters report skin problems or no psychological benefit after a month.

Uncontrolled reports; product identity and concentrations were not verified. Interacting combinations are confounds, not absorption-boosting instructions. No feeling proves longevity benefit.

How does rapamycin make you feel? (opens in a new tab)January 30–31, 2023: #3 jakexb, #6 Arhu, #11 anon16510610, #13 Phil_Van_Treuren, #15 DeStrider.Self-selected unverified reports. DeStrider combines grapefruit/olive oil with other supplements; those interaction confounds cannot be a solo-drug timing estimate.

Other context in this card

Rapamycin: product-specific blood-level comparison (opens in a new tab)Final2025 publisher Results, Figure1, Table1 and competing interests; 24-hour concentration comparison, not AUC or individual dose equivalence; relevant text September6.24-hour concentration, not complete AUC or universal dose equivalence. AgelessRx employee/shareholder interests disclosed; substantial individual variation.
Rapamycin:333-user off-label survey (opens in a new tab)Original333-user survey, printed pp2760–2761 Rapamycin users; weekly percentages and6mg mode; independent researcher read September6.Self-selected respondents; mode is not mean and percentages do not describe all longevity users.
Related everolimus vaccine-response trial (opens in a new tab)Mannick original abstract: RAD001/everolimus and influenza-vaccine response; independent abstract review September6.Abstract-only review; a different rapalog, not evidence of sirolimus dose equivalence.

What people say 22

Autophagy / CR-mimetic story: mTORC1 block framed as cellular cleanup and partial nutrient-sensing mimic without full calorie restriction. forum
Off-label user survey (~333 adults, Kaeberlein et al. 2023 class): Self-report cohort with high perceived QoL; mouth sores the main side that differed vs non-users; selection-biased, not causal lifespan proof. forum
Modal real-world dose in surveys: Among weekly users, 6 mg was the single most common dose (e.g. large male and smaller female weekly subsets both centered on 6 mg in published survey tables). forum
Subjective logs: Some report better recovery, “lower inflammation feel,” energy/stamina, or sharper cognition on weekly use — highly confounded and not PEARL hard endpoints. anecdote
Case-level BMD / stack anecdotes: Isolated case reports (e.g. rapamycin + LDN and BMD change) circulate; not PEARL-class evidence. anecdote
Mouse lifespan (ITP and multi-lab): Mid- or late-life rapamycin extends median and max lifespan; commonly cited ~10–25% median range depending on sex, strain, dose, and start age. animal
Late-life start still works (mice): ITP-style work often cited for start at ~20 months (rough human-60 analogy) still extending life — core “not too late” narrative. animal
Age pathology (preclinical): Delayed some age-linked disease and functional-decline endpoints in mice beyond raw lifespan numbers. animal
ITP combo lore — rapa + acarbose: Among strongest ITP combo signals; male median lifespan gains often retold in the high-20s–30s % range depending on paper/summary. animal
ITP combo lore — rapa + metformin: Discussed as additive vs rapa alone in some summaries; metformin alone is not the ITP standout the way rapamycin is. animal
Immune aging (Mannick / everolimus RAD001): Low-dose intermittent rapalog improved influenza vaccine response ~20% and reduced exhausted PD-1+ T-cell markers in older adults after ~6 weeks (arms included 0.5 mg/day and 5 mg weekly; 20 mg weekly was less favorable / higher mTOR inhibition in discussion). Follow-on TORC1 work (2018) extended infection-rate narratives. trial
PEARL design: 48-week decentralized, double-blind, placebo-controlled trial of intermittent compounded rapamycin in normative older adults (~mean age ~60; ~114 completers often summarized as ~40 on 5 mg, ~35 on 10 mg, ~39 placebo; women minority of cohort). trial
PEARL primary endpoint: Visceral adiposity (DEXA) — not significantly improved vs placebo. trial
PEARL secondary (women, 10 mg compounded): Lean tissue mass improved (~mid-single-digit % range by 48 weeks in common retellings; significant vs placebo/baseline in published analyses) and self-reported pain improved. trial
PEARL secondary (5 mg compounded): Emotional well-being / general-health survey signals reported in some summaries. trial
PEARL safety headline: Adverse-event and serious-AE rates broadly similar to placebo at these intermittent low exposures in trial write-ups; mild GI and mouth sores remain the practical watch items. trial
Compounded-versus-commercial comparison: The older 0.287/28.7% estimate became 31.03% in the final 2025 report, comparing 24-hour blood concentration per labeled milligram (~0.27 vs ~0.87 ng/mL/mg) in studied products. Retold 3–3.5-fold and 5/10 mg compounded ≈ 1.4–2.9 mg generic calculations are not validated dose conversions or total-exposure estimates. Individual variation was substantial. trial
Periodontal / oral-aging interest: Mouse work on periodontal bone/inflammation + FDA-cleared human periodontal rapamycin study talk (UW-linked) keep oral-health endpoints in the research conversation alongside ulcer nuisance. trial
ME/CFS exploratory talk: Observational/open weekly ~6 mg discussions for fatigue/PEM pathways via autophagy framing — early, not longevity proof. forum
Dog Aging Project / TRIAD bridge: Companion-dog PK and TRIAD-style work often cited at ~0.15 mg/kg once weekly as a translational anchor between mice and humans; multi-year canine healthspan/lifespan readout still unfolding. animal
Exercise co-trials honesty: At least one small RCT of weekly ~6 mg sirolimus + home exercise in sedentary older adults did not show enhanced functional gains vs exercise alone (and raised attenuation questions in commentary) — counters “rapa always synergizes with training” lore. trial
Ovarian aging (VIBRANT / related): Columbia-linked pilot talk — e.g. ~5 mg oral once weekly for ~12 weeks in mid-30s–40s reproductive-aging cohorts; early non-peer-reviewed/media summaries claimed slower ovarian aging signals (~20% framing / fewer follicles lost per cycle lore). Not the same as open-ended multi-year longevity charts. trial

Doses people talk about 28

Most-cited longevity band (generic tablets): ~5–7 mg once weekly; ~6 mg/week is the most common weekly amount in the cited user survey (Kaeberlein-class surveys and rapamycin.news culture). forum
Conservative start: ~2–3 mg once weekly before any upward titration (metabolic concern, interaction risk, ulcer history, smaller body size, older/frail users). forum
Standard clinic talk: ~5–6 mg once weekly as the most-named “working” longevity dose on commercial generic sirolimus. forum
Higher intermittent: ~8–10 mg once weekly in some experienced/guided users who tolerate lower doses and accept tighter lab watch (public longevity-figure reports sometimes cite 8–10 mg trials). forum
Fortnightly / biweekly variants: ~10–15 mg every other week appears in community and secondary write-ups as an alternative pulse for those who prefer fewer dose days or want longer washout. forum
Every-other-day minority: Occasional ~1 mg EOD charts aimed at low continuous exposure; far less standardized than once-weekly. forum
Cyclical daily lore (less common): Multi-day-on / multi-day-off patterns appear in older charts; far less standardized than once-weekly. forum
Outlier high intermittent: Community polls mention rare users at very high weekly or multi-weekly pulses (e.g. teens–20+ mg) — not PEARL, not consensus, higher side risk. forum
When to draw a level (if done): On weekly schedules, people argue peak (hours post-dose) vs trough (just before next weekly dose) for different questions; transplant culture is trough-driven — longevity TDM remains ad hoc. forum
Food timing culture: Same day-of-week, same fed/fasted state each dose; some deliberately pair with a moderate-fat meal for absorption consistency. forum
Grapefruit multiplier fight: 2025–2026 forums repeat ~3–5× exposure if GFJ is in the window; some older clinic lore used a splash of juice to stretch tablets. Careful writeups treat that as unpredictable overshoot, not a smart hack. forum
Sunday-morning / rest-day default: Same weekday each week; many pick a rest morning so any fog/GI lands off a heavy lift day. forum
2026 daily 1 mg minority: Older-male short-course ~1 mg/day immune-marker pilot talk is not the weekly longevity chart and is not a reason to copy transplant daily dosing. trialforum
Clinic titration start (common pattern): ~2–4 mg weekly for several weeks, then step up if labs/sides allow. forum
Broad real-world envelope: Most off-label longevity users cluster ~3–10 mg once weekly; doses >10 mg/week often pair with longer intervals (every 10–14 days) so weekly-equivalent still roughly ~5–10 mg. forum
Every-10-day variants: Some use every 10–14 days to cut cumulative exposure, ulcers, or infection anxiety; no head-to-head longevity RCT vs weekly. forum
Weekly vs daily: In the 2023 survey of 333 off-label users, 88.1% of men and 91.8% of women reported weekly use; four respondents reported daily use and other intervals occurred. The older ~98% statement is not supported by this sample. Daily transplant/chronic exposure remains a different context. forum
Oral survey averages: Off-label oral-health / user cohorts often land ~5.7–6.2 mg/week average (female vs male means in published surveys); intermittent-ulcer reporters averaged higher weekly mg (~6.9 mg) than the few persistent-ulcer cases (~3.6 mg) — sensitivity varies. forum
Trough levels (longevity gap): Transplant targets often roughly ~3–20 ng/mL context-dependent (e.g. ~4–12 or ~5–15 ng/mL chromatographic ranges on labels); weekly longevity use is discussed as producing low/sub-immunosuppressive troughs (sometimes framed as aiming nadir <~3 ng/mL) — many longevity users never do TDM. forum
Titration culture: Start low → watch ulcers/labs → step ~1–2 mg at a time after multi-week observation (half-life means changes are slow). forum
Weight-based framing: ~0.075–0.15 mg/kg once weekly (~5–10 mg for a ~70 kg adult) is the common translational range from dog/human longevity write-ups; TRIAD dog target often cited at 0.15 mg/kg weekly. forum
PEARL trial arms: Placebo vs 5 mg vs 10 mg compounded rapamycin once weekly for 48 weeks. The compounded formulation cannot be assumed to match commercial-tablet exposure. trial
Low-dose daily minority: ~1–3 mg daily discussed by some (continuous mTORC1 hit); short academic pilots used ~1 mg/day for weeks — different risk/feel profile than weekly pulses. trial
Transplant context (do not copy as longevity): Weight-based daily dosing after loading dose + trough TDM (often multi-ng/mL targets roughly mid-single digits to teens/20s depending on regimen and CNI co-use) — immunosuppression, not anti-aging charts. trial
PK flags that change “effective dose”: High-fat meals (~+35% AUC vs fasted in classic solution PK), CYP3A4/P-gp inhibitors or inducers, grapefruit, brand vs generic vs compounded formulation. Consistency week-to-week matters more than chasing a single “optimal fat meal.” trial
Interaction “dose multipliers” (do not self-hack): Historical oncology/PK work shows ketoconazole or grapefruit juice can massively raise sirolimus exposure (forum lore maps large dose-reduction math) — discussed as dangerous interaction risk, not a smart longevity stack. trial
Framing: Discussed community/clinic/trial ranges for research and education only — not advice; sirolimus is a prescription immunosuppressant with real infection and metabolic risks. forum
Compounded vs generic (critical bro fight): The studied compounded product produced lower 24-hour blood levels per milligram than commercial tablets. The older 0.287 figure is not a universal conversion; equal labeled milligrams do not guarantee equal exposure. trial

How it may feel 9

Day of dose / 24–48 h: Many feel nothing; minority report mild fatigue, headache, brain fog, or GI the day of / day after the weekly dose. forum
Week 1: Often no acute “buzz”; first mouth-sore watch window begins for ulcer-prone users. forum
Weeks 2–4: Check oral ulcers, mild GI, skin dryness; plan baseline→early lipid/glucose labs if supervised. forum
Months 1–3: First structured lipid, glucose/HbA1c, CBC check-ins in clinic-style protocols; dose hold if infection hits. forum
Months 3–6: Settle weekly mg band or titrate after labs/sides; PEARL-like horizon for tolerability, not life-extension proof. forum
Year 1+: Thin healthy-user hard-outcome data; infection awareness, surgery-hold discipline, and lipid/glucose drift remain the practical long game. forum
Labs > feel: 2026 user posts that actually change practice are lipids, fasting glucose/HbA1c, and a mouth-sore count — not a “longevity buzz.” forum
Month 6–12: PEARL-class talk = safety + biomarkers/self-report, not mortality or multi-year disease prevention. trial
No feel by 8–12 wk: Common and expected — goals are usually labs/healthspan framing, not stimulant-like effects. forum

Around the dose 6

Clock: Same weekday. Morning is common; night can feel stimulating for a subset. Sunday rest-day is a frequent habit so the pulse isn’t on a Monday squat. forum
Fasted vs food: High-fat meals can raise AUC ~35% vs fasted. The actual rule in careful threads is *don’t switch* — same fed/fasted state every week. trialforum
Training: Heavy lifting the same day (and often the next) is the “will this blunt gains?” worry. People who still train put hard sessions later in the week. forum
Grapefruit: Not a dose-extender in current careful talk. Avoid the fruit/juice around the dose unless a clinician is deliberately running that interaction. forum
After: Protein and lifting still do muscle work. Bloodwork (lipids, glucose/HbA1c, CBC) is the pairing, not a second supplement. forum
Hold: Pause talk for infection, and hold around elective surgery / unhealed injury. trialforum

Cycles people discuss 12

Default pattern: Continuous once-weekly long-term use, not short peptide-style 4–8 week cycles. forum
Drug holidays (common clinic lore): Optional 4–8 week pauses every ~3–6 months discussed for theoretical mTOR rebound and cumulative-exposure reduction — not RCT-proven superior to continuous weekly. forum
Hold for infection: Stop or pause on significant illness; intermittent use does not erase infection concern. forum
Hold for mouth sores / lab flags: Temporary dose cut, interval lengthening, or pause after aphthous ulcers, lipid/glucose spikes, or CBC flags. forum
Illness-season caution: Some users lower dose or pause during high-exposure infection seasons or travel — anecdote-level strategy. anecdote
Age culture: Forums/clinics often more cautious under ~40 (growth/muscle/fertility narrative) and more common in 40s–60s+; not a validated age cutoff. forum
Trial blocks: PEARL-style 48-week blocks; Mannick’s related-everolimus ~6-week immune-response blocks; ovarian pilots ~12 weeks; exercise co-trials ~13 weeks; clinic 3–12 month supervised trials with baseline + interval labs. trial
Hold for surgery / major injury: Wound-healing impairment risk — elective surgery holds commonly discussed (≥1 week pre-op and until healing is clear; some protocols extend longer; practices vary). trial
Vaccine timing talk: Mannick’s related-everolimus data used to argue intermittent low-dose may support inactivated flu vaccine responses when timed around a short course; live-vaccine caution still appears on product labels for immunosuppressive use. trial
Long-term data gap: Multi-year/decade healthy weekly-use safety and hard endpoints still developing; PEARL is ~1 year class. trial
Pregnancy / planning: Pregnancy avoidance is a labeled precaution; an ordinary cycling break does not establish pregnancy safety. trial
RAPA-EX-01 (2026): Weekly ~6 mg sirolimus + 13-week home exercise in sedentary older adults (Stanfield et al., J Cachexia Sarcopenia Muscle) did not enhance function vs exercise alone and reported more total AEs (minor infections/constitutional). Counters “just add rapa to training.” trial

Timing 11

Why weekly is plausible: Long half-life + intermittent mTORC1 hit with partial recovery between doses is the core longevity PK story (“pulse then washout”). forum
TDM practice split: Transplant = routine trough monitoring; longevity = optional “confirm absorption” labs or skip; longevity troughs often discussed as low/sub-transplant. forum
Downstream labs that matter more than “feel”: Fasting lipids (LDL, TG), ApoB if used, glucose/HbA1c, CBC; some also track hs-CRP, DEXA body composition, or broader panels in clinic stacks. forum
Lipid/glucose as over-inhibition signals: Rising lipids or glucose sometimes framed in community talk as possible mTORC2 engagement cue to cut dose or lengthen interval. forum
Clearance folklore: “Clears in ~10–14 days” summaries based on multi-half-life washout — used to justify biweekly schedules and surgery holds. forum
Half-life (sirolimus): Mean terminal blood elimination was about 62 ± 16 hours after repeated dosing in stable renal-transplant patients. Older ~60 hour/~50–70+ hour shorthand is not a single-dose coverage or felt-duration estimate. trial
Steady state / change lag: The label describes 7–14 days on an adjusted maintenance dose before further concentration-guided adjustment. The older 5–7+ day wording did not establish when side effects can be judged. trial
mTORC1 vs mTORC2 framing: Acute/intermittent exposure hits mTORC1 more readily; chronic high/daily exposure more likely to engage mTORC2-related metabolic downsides (insulin resistance narratives) — bro rationale for weekly pulses over daily transplant-style dosing. forum
Food effect is formulation-specific: The Rapamune label reports 23–35% higher AUC with a high-fat meal in healthy subjects, but the peak-concentration effect differs between oral solution and tablets. A universally lower peak is not established. Consistent food context is distinct from using interactions to boost exposure. trial
Metabolism / transporters: CYP3A4 and P-glycoprotein dominant — azoles (ketoconazole, etc.), some macrolides, diltiazem/verapamil, grapefruit ↑ exposure; rifampin, some anticonvulsants, St. John’s wort ↓ exposure. trial
Everolimus contrast (related rapalog): Higher oral bioavailability but shorter half-life (forum/clinical summaries often ~28–30 hr vs sirolimus ~60+ hr) — Mannick immune trials used everolimus, not always interchangeable mg-for-mg with sirolimus longevity charts. trial

Stacks 13

Metformin: Most-named dual stack — AMPK + mTOR nutrient-sensing; also discussed as metabolic offset for rapa-related glucose/TG drift. Doses are separate drugs (not a fixed ratio blend); common metformin talk is standard IR/XR clinical bands, not “X mg per mg rapa.” forum
Metformin + acarbose + rapa “trio”: Forum longevity polypharmacy charts; animal synergy stories, human stack evidence thin. forum
NAD axis (NMN/NR): Often co-logged in multi-agent longevity stacks — hard to isolate credit; no required washout from weekly rapa in common talk. forum
Senolytics on separate calendar: Dasatinib+quercetin (D+Q) or fisetin pulses timed away from weekly rapa day in some protocols (hit-and-run senolytic blocks vs continuous weekly rapa). forum
Spermidine / polyamine talk: Autophagy-adjacent stack neighbor in supplement charts. forum
Statins / lipid management: Blagosklonny-style and clinic talk of managing rapa-related lipids (statin or lifestyle) rather than abandoning the drug. forum
SGLT2 / metabolic neighbors: Occasional modern clinic stacks for glucose control alongside rapa — discussion-level, not a fixed ratio protocol. forum
LDN (low-dose naltrexone): Minority co-use anecdotes (immune/pain/BMD case chatter); not a standard ratio stack. anecdote
Acarbose: ITP-famous combo with rapamycin (strong male mouse lifespan synergy talk); human co-use appears in metabolic/longevity threads (carb-blocker timing with meals, not on rapa day specifically). animal
Trametinib (preclinical combo): MEK inhibitor + rapa combo lifespan talk in animal/academic circles — not a common human clinic stack. animal
Exercise confounder: Training, sleep, and calorie moderation are constant confounds; at least one human exercise+rapa trial did not show synergy for function. trial
Lifestyle first framing: Serious write-ups still put training, sleep, BP, and metabolic hygiene above drug stacking. forum
What people do not stack casually: Strong CYP3A4 inhibitors (azole antifungals, etc.) and grapefruit — interaction risk, not enhancement protocol. trial

Access talk 1

[object Object]

Storage notes 3

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Oral product (this card): Rapamycin/sirolimus in longevity talk is a tablet or compounded capsule — not a BAC-water peptide mix. Storage follows the pharmacy label (solution forms have extra measuring-error talk). forum

Related 8

Watch for 23

Mouth sores (most common nuisance): Aphthous oral ulcers; longevity-dose reports often roughly teens % at some point (PEARL and survey ranges commonly retold ~10–20% class; transplant/higher exposure literature much higher). Intermittent more than persistent in surveys. forum
Ulcer dose notes (survey): Off-label oral-health work — e.g. ~54 ulcer reports among users with oral outcomes (50 intermittent, 4 persistent); intermittent-ulcer reporters averaging higher weekly mg (~6.9 mg) than few persistent-ulcer cases (~3.6 mg) — individual sensitivity matters more than a single threshold. forum
GI: Nausea, diarrhea, abdominal discomfort; PEARL and user reports often list mild GI alongside ulcers as top nuisances. forum
Skin: Dry skin / rash discussions at higher weekly exposure. forum
Sourcing: Gray-market powder and unverified overseas product add purity/dose risk beyond the molecule’s own pharmacology; compounded vs generic exposure mismatch is a separate real-world trap. forum
Not risk-free at “longevity dose”: Soft community language (“just 6 mg weekly”) coexists with real lab and infection monitoring culture among careful users. forum
Infection is not theoretical: Even weekly longevity use keeps a pause-when-sick culture; RAPA-EX-01’s extra AE burden was partly infectious/constitutional. trialforum
Lipids / glucose bloodwork: LDL/TG and glucose drift are the lab arguments at weekly doses — check, don’t guess. trialforum
Access: Off-label prescription (generic sirolimus) vs telehealth compounded capsules vs unverified powder — three different exposure/purity stories. forum
Infection risk: Real immunosuppressant class concern; intermittent low-dose does not erase it — pause talk on significant illness; rare serious infections still appear in case/trial commentary. trial
Wound healing: Can delay repair — hold for elective surgery or major injury per clinical caution. trial
Metabolic — lipids: Higher cholesterol/triglycerides with exposure; common lab watch item even at weekly doses. trial
Metabolic — glucose: Glucose intolerance / higher fasting glucose risk; some users cut dose, lengthen interval, or add metabolic agents rather than ignore drift. trial
CBC flags: Anemia, thrombocytopenia, leukopenia documented in clinical sirolimus use — less common at longevity intermittent doses but still monitored. trial
Edema / angioedema: Documented in clinical sirolimus use; less central to longevity forum lore than ulcers/lipids. trial
Lung (rare, serious): Interstitial lung disease / pneumonitis is uncommon but labeled/clinical concern. trial
Malignancy class risk: Product labeling includes lymphoma/skin cancer concern under chronic immunosuppression context — longevity intermittent risk magnitude uncertain. trial
Fertility / pregnancy / breastfeeding: Label warnings include fetal harm based on animal evidence, possible impaired fertility and potentially serious effects in breastfed infants. Human pregnancy/lactation data are limited; ovarian-aging trials do not establish safety in these settings. animaltrial
Muscle / training debate: Mouse anabolism concerns and mixed human exercise-trial signals keep “will rapa kill my gains?” alive; PEARL lean-mass signal in women on higher compounded arm cuts against simple catabolic fear but does not settle training optimization. trial
Interactions: Strong CYP3A4 inhibitors (azole antifungals, some macrolides) can swing levels hard; grapefruit routinely banned in careful protocols; inducers can under-dose. trial
Live vaccines: Label-style caution under immunosuppressive use; contrast with Mannick low-dose vaccine-response improvement narrative for inactivated flu vaccine context. trial
Sirolimus on the bottle: If the pharmacy label says sirolimus, it is rapamycin. Compounded “rapamycin” mg ≠ generic tablet mg. trial
Grapefruit / CYP3A4: Azoles, some macrolides, and GFJ can swing levels hard. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 22

Doses people talk about 28

How it may feel 9

Around the dose 6

Cycles people discuss 12

Timing 11

More on what it is 7

Stacks 13

Access talk 1

Storage notes 3

Related 8

Watch for 23

Timing context & sources